Perioperative Anticoagulation Bridging: When, Why, and How?

Visual Element: An interactive "Bridging Calculator". User inputs patient risk factors (Mechanical Valve, AF stroke risk) and surgery bleeding risk to get a "Bridge / No Bridge" recommendation.

Managing anticoagulation in the peri-operative period is high-stakes poker. Throughout your orthopaedic surgery training, you will constantly navigate the delicate balance between preventing catastrophic thromboembolic events and avoiding devastating surgical site bleeding. Stop the drugs too early, and the patient suffers a massive stroke, pulmonary embolism, or mechanical valve thrombosis. Stop them too late—or bridge them unnecessarily—and you cause a spinal epidural hematoma or a massive infected joint hematoma requiring multiple washouts and potentially leading to periprosthetic joint infection (PJI).

The old dogma in surgical education was elegantly simple but inherently flawed: "Admit everyone on Warfarin 5 days early, stop their oral agents, and bridge with intravenous Heparin or subcutaneous Enoxaparin."

This is definitively wrong. Modern evidence has shattered this paradigm. The landmark BRIDGE trial (2015) and subsequent high-quality studies have unequivocally shown that for the vast majority of patients—especially those with standard Atrial Fibrillation (AF)—bridging causes significantly more harm through major surgical bleeding than it does good in preventing strokes.

Whether you are managing a complex elective revision arthroplasty or preparing a trauma patient for theatre, this guide outlines the modern, evidence-based, risk-stratified approach. Mastering these concepts is absolutely critical for your clinical practice and forms a core pillar of your fellowship exam preparation.

Part 1: Warfarin (Vitamin K Antagonists)

Warfarin remains notoriously tricky because of its unpredictable pharmacokinetics, narrow therapeutic index, and long half-life (typically 36-42 hours, but variable depending on liver function and diet). Managing it requires meticulous planning.

To Bridge or Not to Bridge?

The decision to bridge is no longer a blanket "yes." You must carefully stratify the patient's baseline Thromboembolic Risk. We assess this using their underlying pathology and validated scoring systems like CHA₂DS₂-VASc.

High Risk (MUST BRIDGE - Strong Indication):

• Mechanical Heart Valves: Any mechanical mitral valve prosthesis, or older generation aortic valves (caged-ball or tilting disc). Patients who have had a stroke or TIA within the last 6 months regardless of valve type.
• Atrial Fibrillation (AF): Severe risk patients with a CHA₂DS₂-VASc score of 7-9 (or the older CHADS₂ score of 5-6). Recent stroke or TIA within the last 3 months. Rheumatic valvular heart disease.
• Venous Thromboembolism (VTE): A documented Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) within the last 3 months. Patients with severe, high-risk thrombophilias (e.g., Antithrombin III deficiency, Protein C/S deficiency, or Antiphospholipid syndrome).

Moderate Risk (Consider Bridging - Individualized Clinical Judgement):

• AF: CHA₂DS₂-VASc score of 4-6. Here, you must weigh the patient's individual bleeding risk against their stroke risk. Discuss with cardiology or haematology.
• VTE: History of a VTE event occurring between 3 and 12 months ago, or non-severe thrombophilia (e.g., heterozygous Factor V Leiden).

Low Risk (DO NOT BRIDGE - Washout Only):

• AF: CHA₂DS₂-VASc score of 0-3 without prior stroke.
• VTE: Remote history of a provoked VTE occurring more than 12 months ago.
• Mechanical Valve: Bileaflet mechanical aortic valve without any other stroke risk factors.

The Standard Perioperative Warfarin Protocol

For a patient undergoing major orthopaedic surgery (e.g., Total Hip Arthroplasty) who requires bridging, the timeline must be precise:

• Day -5: Cease Warfarin completely.
• Day -3: Commence Therapeutic Enoxaparin (Clexane) at 1mg/kg BD (or Dalteparin equivalent) IF the patient meets bridging criteria.
• Day -1 (Morning): Check INR. If the INR is still > 1.5, administer oral Vitamin K 1-2mg to gently reverse the residual effect without causing prolonged warfarin resistance post-operatively.
• Day -1 (Evening): Give the final dose of Enoxaparin exactly 24 hours prior to the anticipated surgical incision.
• Day 0: Surgery. Ensure rigorous intraoperative hemostasis. Do not rely on drains to manage sloppy surgical technique.
• Day +1: Restart Warfarin at the patient's usual maintenance dose (do not give a massive loading dose, as this precipitates a hypercoagulable state by depleting Protein C). Restart Enoxaparin. Note: In orthopaedics, due to the high risk of catastrophic surgical site hematoma, we typically restart prophylactic dose Enoxaparin on Day 1, delaying the resumption of therapeutic bridging until 48-72 hours post-op, once the bleeding risk has stabilized.

Part 2: Direct Oral Anticoagulants (DOACs)

DOACs—such as Apixaban (Eliquis), Rivaroxaban (Xarelto), and Dabigatran (Pradaxa)—have revolutionized outpatient anticoagulation. They possess rapid onset, predictable pharmacokinetics, and crucially, short half-lives (~10-14 hours).

Bridging is NEVER indicated for patients on DOACs. The "bridge" is simply the natural pharmacokinetic washout of the drug. Attempting to bridge a DOAC with LMWH dramatically increases major bleeding without any thromboembolic benefit, a fact proven by the PAUSE trial (2019).

Stopping Rules (Assuming Normal Renal Function)

The duration of cessation depends entirely on the bleeding risk of the surgical procedure.

• Low Bleeding Risk Procedures:
  • Orthopaedic Examples: Knee/shoulder arthroscopy, carpal tunnel release, trigger finger release, minor foot and ankle surgery (e.g., hardware removal).
  • Action: Stop 24 hours prior to surgery (skip 2 doses for BD drugs like Apixaban, 1 dose for daily drugs like Rivaroxaban).
• High Bleeding Risk Procedures:
  • Orthopaedic Examples: Primary and revision arthroplasty, multilevel spinal decompression and fusion, pelvic and acetabular trauma, major osteotomies.
  • Action: Stop 48 to 72 hours prior to surgery (skip 4-6 doses).

Adjustments for Renal Impairment

• Dabigatran: If CrCl is < 50 mL/min, you must stop the drug 4 to 5 days prior to high-risk orthopaedic surgery.
• Apixaban/Rivaroxaban: While less renally dependent (~25-30% renal clearance), you must still extend the cessation period to 72-96 hours if the CrCl drops below 30 mL/min.

Part 3: Neuraxial Anaesthesia (Spinal/Epidural)

This is frequently a surgeon's blind spot, but it is a critical area of surgical education. You might be perfectly happy to operate through a bit of a venous ooze, but the anaesthetist will flatly refuse to place a spinal needle if the coagulation profile isn't pristine.

An epidural or spinal hematoma is a devastating complication that leads to irreversible spinal cord or cauda equina compression and paraplegia. Decompression must occur within 6-8 hours to salvage function. To prevent this, the ASRA (American Society of Regional Anesthesia) Guidelines act as the global medico-legal standard. Memorize these intervals for your exams.

Clinical Pearl: If the anaesthetist performs a "bloody tap" (trauma to the epidural venous plexus during needle insertion), surgery may still proceed under general anaesthesia, but the initiation of post-operative VTE prophylaxis (like LMWH) must be delayed by a minimum of 24 hours to prevent a delayed hematoma.

Part 4: Antiplatelet Agents

Managing antiplatelets is less about major blood loss and more about avoiding devastating cardiac events.

Elective Surgery Management

• Aspirin: Following the POISE-2 trial, the modern consensus is that Aspirin is generally CONTINUED for most orthopaedic patients taking it for secondary cardiovascular prevention. The catastrophic risk of perioperative myocardial infarction or stent thrombosis far outweighs the mild, manageable increase in surgical oozing.
  • Exception: Intracranial surgery, or major multilevel spinal deformity surgery where microscopic visualization is critical and epidural bleeding is poorly tolerated (usually dictated by surgeon preference).
• P2Y12 Inhibitors (Clopidogrel / Ticagrelor / Prasugrel): These profoundly inhibit platelet aggregation. They must be stopped 5-7 days prior to elective orthopaedic surgery to allow for the generation of fresh, uninhibited platelets from the bone marrow.

The Coronary Stent Patient

This is the highest-risk cardiac patient you will operate on. Understanding stent timelines is a frequent hurdle in fellowship exam preparation.

• Bare Metal Stent (BMS): Elective surgery must be delayed for a minimum of 4-6 weeks post-placement to allow for endothelialization.
• Drug Eluting Stent (DES): Older generations required a 12-month delay. Current ACC/AHA guidelines suggest elective non-cardiac surgery can safely proceed after a minimum of 6 months (sometimes 3 months in highly selected patients after cardiology review).
• The Danger Zone: If you must operate within this critical window (e.g., an emergent fracture).

Part 5: Emergency Reversal in Orthopaedic Trauma

You are the senior registrar in the trauma bay. An 82-year-old patient has fallen down the stairs, sustaining an open tibia-fibula fracture and an unstable pelvic ring injury. They are taking Rivaroxaban for AF. They are bleeding. What do you do?

1. Mechanical Hemostasis: Tourniquets, pelvic binders, and direct pressure are your first line. Do not wait for drugs to work if you can stop the bleeding mechanically.
2. Tranexamic Acid (TXA): 1g IV over 10 minutes, followed by 1g over 8 hours (CRASH-2 protocol). TXA is an antifibrinolytic; it prevents clot breakdown. Give it to almost every bleeding trauma patient early.
3. Specific Reversal Agents:
   • Idarucizumab (Praxbind): A monoclonal antibody specifically designed for Dabigatran. It provides instant, complete reversal. Dose is 5g IV.
   • Andexanet Alfa: A recombinant decoy receptor for Apixaban and Rivaroxaban. It rapidly reverses anti-Factor Xa activity. However, it is astronomically expensive and not available in all centers.
   • Prothrombin Complex Concentrate (PCC - e.g., Prothrombinex or Kcentra): Contains Factors II, IX, and X (and VII in 4-factor PCCs). This is the gold standard for rapid Warfarin reversal (always given alongside 5-10mg IV Vitamin K). Because Andexanet Alfa is scarce, high-dose PCC (typically 50 units/kg) is widely used off-label as the standard rescue therapy for life-threatening bleeding in patients on Apixaban or Rivaroxaban.

Conclusion

The core philosophy of peri-operative medicine in orthopaedics is minimizing the "Time at Risk."

• Minimize the time the patient is off their drugs to prevent devastating clots and strokes.
• Minimize the drug effect during the exact hours of surgery to prevent catastrophic bleeds and hematomas.
• Stop the outdated practice of bridging low and moderate-risk patients.

By moving away from dogma and embracing risk-stratified, evidence-based protocols, you protect your patients, your surgical outcomes, and demonstrate the sophisticated clinical reasoning required to pass your fellowship exams and excel as an orthopaedic consultant.

ASRA Guidelines App

Download the official ASRA Coags app for real-time guidance on neuraxial anesthesia intervals. An essential tool for every orthopaedic registrar's phone.